2022 Blue Faery Award Nomination Period Opens

AA

A A

2022 Blue Faery Award Nomination Period Opens

On November 1, the 2022 Blue Faery Award for Excellence in Liver Cancer Research open for nominations. We have switched from an email submission process to an electronic form. For more details including the 2022 guidelines, go to our Blue Faery Award page.

 

Dr. Xin W. Wang Wins 2021 Blue Faery Award

Dr Xin Wang
Dr. Xin W. Wang, Senior Investigator at the National Cancer Institute, wins Blue Faery Award twice

As a Senior Investigator at the National Cancer Institute (NCI), Dr. Wang has dedicated his professional life to improving early detection, diagnosis and treatment of liver cancer for over 25 years. He is also co-Director of the Multidisciplinary CCR Liver Cancer Program, Deputy Lab Chief of the CCR Laboratory of Human Carcinogenesis and co-PI of the CCR Liver Moonshot CLARITY. Dr. Wang applies genome-scale technologies paired with several international collaborative initiatives and clinical studies. He has co-authored over 200 scientific articles including a recent study published in Cell.

Upon receiving the BFA Dr. Wang stated, “I am so thrilled to hear this wonderful news. It’s an absolute honor to receive this year’s award, especially in the midst of the COVID-19 pandemic and as the recipient who has ever won this award twice. Thanks to the board for recognizing our works.”

See previous Blue Faery Award Winners here.

Dr. Ann-Lii Cheng Wins 2020 Blue Faery Award

Dr. Ann-Lii Cheng Wins 2020 Blue Faery Award for Excellence in Liver Cancer Research

Professor Ann-Lii Cheng has contributed significantly to the basic knowledge and clinical application of molecular targeted therapy and immunotherapy in hepatocellular carcinoma (HCC). Living in the part of the world plagued by HCC, Prof. Cheng has devoted his career to substantiating a solution. Since 2004, he has been involved in the development of sorafenib and lenvatinib, two pivotal drugs in the first-line treatment of HCC, and recently the discovery of a new regimen, atezolizumab plus bevacizumab, which is considered an epoch-making breakthrough in this field. His research team at National Taiwan University has been recognized as one of the most prominent translational research groups in exploring the frontier of HCC treatment.